BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+27.7%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$18.4B
AUM Growth
+$18.4B
(+10%)
Cap. Flow
-$969M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
90.4%
Holding
120
New
7
Increased
23
Reduced
7
Closed
13
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$53.5M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$31.5M |
| 3 |
Roivant Sciences
ROIV
|
$30M |
| 4 |
FibroGen
FGEN
|
$23.6M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$15M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.5B | 51.68% | 46,913,769 +1,503 | +0% | +$304K |
|
2
Incyte
INCY
$16.5B
| $2.61B | 14.22% | 36,175,400 +20,429 | +0.1% | +$1.48M |
|
|
ONC
3
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.51B | 13.68% | 11,668,897 | – | – |
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $789M | 4.29% | 41,938,486 +15,000 | +0% | +$282K |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $374M | 2.04% | 1,545,113 | – | – |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $371M | 2.02% | 3,810,248 -3,810,246 | -50% | -$371M |
|
7
Immunocore
IMCR
$1.62B
| $125M | 0.68% | 2,520,731 | – | – |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $116M | 0.63% | 6,498,267 +143,659 | +2% | +$2.56M |
|
9
Kodiak Sciences
KOD
$478M
| $107M | 0.58% | 17,310,490 | – | – |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $106M | 0.58% | 12,710,818 | – | – |
|
11
argenx
ARGX
$43.6B
| $104M | 0.57% | 280,159 | – | – |
|
12
Akero Therapeutics
AKRO
$3.74B
| $90.6M | 0.49% | 2,368,378 | – | – |
|
13
Kymera Therapeutics
KYMR
$2.95B
| $85.3M | 0.46% | 2,879,825 | – | – |
|
14
Replimune Group
REPL
$422M
| $80.9M | 0.44% | 4,578,280 | – | – |
|
15
AbCellera Biologics
ABCL
$1.25B
| $78.8M | 0.43% | 10,450,180 | – | – |
|
|
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
| $70.9M | 0.39% | 2,753,502 +1,224,964 | +80% | +$31.5M |
|
17
Entrada Therapeutics
TRDA
$208M
| $70.6M | 0.38% | 4,865,819 | – | – |
|
18
Biomea Fusion
BMEA
$116M
| $65.4M | 0.36% | 2,108,949 +4,390 | +0.2% | +$136K |
|
|
19
Revolution Medicines
RVMD
$7.1B
| $58.3M | 0.32% | 2,691,493 +2,469,271 | +1,111% | +$53.5M |
|
20
Prelude Therapeutics
PRLD
$68.5M
| $57.7M | 0.31% | 10,123,824 | – | – |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $52.4M | 0.29% | 1,409,784 | – | – |
|
|
22
FibroGen
FGEN
$47.8M
| $49.2M | 0.27% | 2,637,384 +1,262,173 | +92% | +$23.6M |
|
23
Cerus
CERS
$251M
| $47.7M | 0.26% | 16,067,558 | – | – |
|
|
IGMS
24
DELISTED
IGM Biosciences
IGMS
| $43.4M | 0.24% | 3,156,656 +554 | +0% | +$7.61K |
|
|
JBIO
25
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $39.6M | 0.22% | 1,963,479 -13,389 | -0.7% | -$270K |
|